Aktis Oncology, Inc. Common stock Asset Resilience Ratio
Aktis Oncology, Inc. Common stock asset resilience ratio. Aktis Oncology, Inc. Common stock (AKTS) has an Asset Resilience Ratio of 23.64% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See AKTS cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Aktis Oncology, Inc. Common stock (2022–2024)
Asset resilience ratio of Aktis Oncology, Inc. Common stock from 2022 to 2024. This chart shows how Aktis Oncology, Inc. Common stock's Asset Resilience Ratio has changed over time. Read Aktis Oncology, Inc. Common stock (AKTS) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Aktis Oncology, Inc. Common stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see AKTS current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $65.97 Million | 23.64% |
| Total Liquid Assets | $65.97 Million | 23.64% |
Asset Resilience Insights
- Good Liquidity Position: Aktis Oncology, Inc. Common stock maintains a healthy 23.64% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Aktis Oncology, Inc. Common stock Industry Peers by Asset Resilience Ratio
Compare Aktis Oncology, Inc. Common stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Aktis Oncology, Inc. Common stock Asset Resilience Ratio by Year (2022–2024)
Aktis Oncology, Inc. Common stock asset resilience ratio by year from 2022 to 2024. The table below shows the annual Asset Resilience Ratio data for Aktis Oncology, Inc. Common stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 79.71% | $260.01 Million | $326.18 Million | +23.85pp |
| 2023-12-31 | 55.86% | $68.35 Million | $122.36 Million | -- |
| 2022-12-31 | 0.00% | $0.00 | $138.32 Million | -- |
About Aktis Oncology, Inc. Common stock
Aktis Oncology, Inc. operates as a clinical-stage oncology company that engages in the development of targeted radiopharmaceutical therapies for cancer treatment. The company offers a miniprotein radioconjugate platform to discover and develop radiopharmaceutical therapies that deliver the tumor-killing properties of radioisotopes. It offers Nectin-4, a miniprotein radioconjugate for the treatmen… Read more